Drug intelligence / Profile preview

adalimumab + certolizumab pegol + infliximab

Development stage: Unknown
Lead developer: AbbVie
Modality: Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Subcutaneous, Intravenous

Overview

This is a combination of three separate TNF-alpha inhibitors: adalimumab, certolizumab pegol, and infliximab. These biologics are used to treat various inflammatory conditions including rheumatoid arthritis, Crohn's disease, psoriatic arthritis, ankylosing spondylitis, and plaque psoriasis. While they share the same primary target (TNF-alpha), they differ in structure and some aspects of their mechanism. Adalimumab is a fully human monoclonal antibody, certolizumab pegol is a pegylated antibody fragment lacking the Fc region, and infliximab is a chimeric monoclonal antibody.

Targets

TNFA (Tumor necrosis factor alpha (soluble))

Beyond the preview

Go deeper on adalimumab + certolizumab pegol + infliximab.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on adalimumab + certolizumab pegol + infliximab.

Explore the full profile